A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
Martin H VossRupal S BhattNicholas J VogelzangMayer FishmanRobert S AlterBrian I RiniJ Thaddeus BeckMonika JoshiRalph HaukeMichael B AtkinsEarle BurgessTheodore F LoganDavid ShafferRahul ParikhNauman MoazzamXiaosha ZhangChad GlasserMatthew L ShermanElizabeth R PlimackPublished in: Cancer (2019)
Although well tolerated, the addition of dalantercept to axitinib did not appear to improve treatment-related outcomes in previously treated patients with advanced RCC.